Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
| Autor: | Alexandra U Scherrer, Bruno Ledergerber, Viktor von Wyl, Jürg Böni, Sabine Yerly, Thomas Klimkait, Cristina Cellerai, Hansjakob Furrer, Alexandra Calmy, Matthias Cavassini, Luigia Elzi, Pietro L Vernazza, Enos Bernasconi, Huldrych F Günthard, Swiss HIV Cohort Study |
|---|---|
| Přispěvatelé: | University of Zurich, Swiss HIV Cohort Study, Remy, B., Rickenbach, M., Schöni-Affolter, F., Vallet, Y., Francioli, MC., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S. |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
10028 Institute of Medical Virology lcsh:Medicine HIV Infections medicine.disease_cause Gastroenterology Nucleoside Reverse Transcriptase Inhibitor 10234 Clinic for Infectious Diseases 0302 clinical medicine HIV Protease HIV Protease Inhibitor 030212 general & internal medicine lcsh:Science ddc:616 0303 health sciences Mutation Multidisciplinary Hazard ratio HIV diagnosis and management Viral Load 3. Good health HIV epidemiology Cohort RNA Viral Medicine Infectious diseases HIV clinical manifestations Female Viral load Research Article medicine.medical_specialty Retrovirology and HIV immunopathogenesis Sexually Transmitted Diseases 610 Medicine & health Viral diseases 1100 General Agricultural and Biological Sciences Biology 03 medical and health sciences CD4 Lymphocyte Count Drug Resistance Viral/genetics HIV Infections/drug therapy HIV Infections/virology HIV Protease/genetics HIV Protease Inhibitors/pharmacology HIV Protease Inhibitors/therapeutic use Humans RNA Viral/blood 1300 General Biochemistry Genetics and Molecular Biology Internal medicine Drug Resistance Viral medicine Genetics HIV Protease Inhibitors/pharmacology/therapeutic use Protease inhibitor (pharmacology) HIV Infections/drug therapy/virology 030304 developmental biology Evolutionary Biology 1000 Multidisciplinary Population Biology Proportional hazards model lcsh:R Computational Biology HIV HIV Protease Inhibitors Immunology Genetic Polymorphism 570 Life sciences biology lcsh:Q Population Genetics |
| Zdroj: | PLOS ONE, Vol. 7, No 6 (2012) P. e37983 PLoS ONE, Vol 7, Iss 6, p e37983 (2012) PLoS ONE; Vol 7 PloS one PLoS ONE Scherrer, Alexandra U.; Ledergerber, Bruno; von Wyl, Viktor; Böni, Jürg; Yerly, Sabine; Klimkait, Thomas; Cellerai, Cristina; Furrer, Hansjakob; Calmy, Alexandra; Cavassini, Matthias; Elzi, Luigia; Vernazza, Pietro L.; Bernasconi, Enos; Günthard, Huldrych F.; Swiss HIV Cohort Study, (2012). Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PLoS ONE, 7(6), e37983. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0037983 Plos One, vol. 7, no. 6, pp. e37983 |
| ISSN: | 1932-6203 |
| DOI: | 10.5167/uzh-67852 |
| Popis: | Background Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naive patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential. Methods To study the impact of minor PI mutations on time to viral suppression and time to virological failure, we included patients from the Swiss HIV Cohort Study infected with HIV-1 subtype B who started first-line ART with a PI and two nucleoside reverse transcriptase inhibitors. Cox regression models were performed to compare the outcomes among patients with 0 and ≥1 minor PI mutation. Models were adjusted for baseline HIV-1 RNA, CD4 cell count, sex, transmission category, age, ethnicity, year of ART start, the presence of nucleoside reverse transcriptase inhibitor mutations, and stratified for the administered PIs. Results We included 1199 patients of whom 944 (78.7%) received a boosted PI. Minor PI mutations associated with the administered PI were common: 41.7%, 16.1%, 4.7% and 1.9% had 1, 2, 3 or ≥4 mutations, respectively. The time to viral suppression was similar between patients with 0 (reference) and ≥1 minor PI mutation (multivariable hazard ratio (HR): 1.1 [95% confidence interval (CI): 1.0–1.3], P = .196). The time to virological failure was also similar (multivariable HR:.9 [95% CI:.5–1.6], P = .765). In addition, the impact of each single minor PI mutation was analyzed separately: none was significantly associated with the treatment outcome. Conclusions The presence of minor PI mutations at baseline has no effect on the therapy outcome in HIV infected individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|